Effects of Ivabradine on Residual Myocardial Ischemia After PCI
Status:
Completed
Trial end date:
2017-03-07
Target enrollment:
Participant gender:
Summary
This is a randomized pharmacological study evaluating the effects of ivabradine in patients
with residual angina after PCI. The role of ivabradine in patients with angina, without
systolic dysfunction, is not yet clear. The investigators performed in all patients an
echostress to evaluate the effects of therapy with ivabradine after 30 days in terms of
exercise tolerance and diastolic function.